{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T08:05:45Z","timestamp":1794989145371,"version":"4.9.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1038\/s41579-023-00861-x","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T07:03:55Z","timestamp":1675667035000},"page":"211-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":434,"title":["The WHO fungal priority pathogens list as a game-changer"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1862-6402","authenticated-orcid":false,"given":"Matthew C.","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5626-2251","authenticated-orcid":false,"given":"David W.","family":"Denning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"861_CR1","unstructured":"World Health Organization. WHO fungal priority pathogens list to guide research, development and public health action. WHO https:\/\/www.who.int\/publications\/i\/item\/9789240060241 (2022)."},{"key":"861_CR2","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","volume":"17","author":"R Rajasingham","year":"2017","unstructured":"Rajasingham, R. et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect. Dis. 17, 873\u2013881 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"861_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/jof3040057","volume":"3","author":"F Bongomin","year":"2017","unstructured":"Bongomin, F., Gago, S., Oladele, R. O. & Denning, D. W. Global and multi-national prevalence of fungal diseases \u2014 estimate precision. J. Fungi (Basel) 3, 57 (2017).","journal-title":"J. Fungi (Basel)"},{"key":"861_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.mib.2019.05.008","volume":"52","author":"J Rhodes","year":"2019","unstructured":"Rhodes, J. & Fisher, M. C. Global epidemiology of emerging Candida auris. Curr. Opin. Microbiol. 52, 84\u201389 (2019).","journal-title":"Curr. Opin. Microbiol."},{"key":"861_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","volume":"20","author":"MC Fisher","year":"2022","unstructured":"Fisher, M. C. et al. Tackling the emerging threat of antifungal resistance to human health. Nat. Rev. Microbiol. 20, 557\u2013571 (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"861_CR6","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01397-19","author":"A Casadevall","year":"2019","unstructured":"Casadevall, A., Kontoyiannis, D. P. & Robert, V. On the emergence of Candida auris: climate change, azoles, swamps, and birds. mBio https:\/\/doi.org\/10.1128\/mBio.01397-19 (2019).","journal-title":"mBio"},{"key":"861_CR7","unstructured":"Global Action For Fungal Infections. Diagnostics for fungal disease in Africa. GAFFI https:\/\/gaffi.org\/africa-diagnostic-reports\/ (2022)."},{"key":"861_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005575","volume":"11","author":"SF Molloy","year":"2017","unstructured":"Molloy, S. F. et al. Cryptococcal meningitis: a neglected NTD? PLoS Negl. Trop. Dis. 11, e0005575 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"861_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43210-w","volume":"9","author":"TE Rocke","year":"2019","unstructured":"Rocke, T. E. et al. Virally-vectored vaccine candidates against white-nose syndrome induce anti-fungal immune response in little brown bats (Myotis lucifugus). Sci. Rep. 9, 6788 (2019).","journal-title":"Sci. Rep."},{"key":"861_CR10","doi-asserted-by":"publisher","first-page":"100885","DOI":"10.1016\/j.drup.2022.100885","volume":"65","author":"PE Verweij","year":"2022","unstructured":"Verweij, P. E. et al. Dual use of antifungals in medicine and agriculture: how do we help prevent resistance developing in human pathogens? Drug Resist. Updat. 65, 100885 (2022).","journal-title":"Drug Resist. Updat."}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41579-023-00861-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-023-00861-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-023-00861-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:34:44Z","timestamp":1733938484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41579-023-00861-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["861"],"URL":"https:\/\/doi.org\/10.1038\/s41579-023-00861-x","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"assertion":[{"value":"6 February 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.C.F. has been paid for talks on behalf of Gilead. D.W.D. and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company that is developing Olorofim, and share options in TFF Pharma. D.W.D. acts or has recently acted as a consultant to Pulmatrix, Pulmocide, Biosergen, TFF Pharmaceuticals, Pfizer, Omega, Novacyt, Rostra Therapeutics, MucPharm and Cipla. D.W.D. sat on the Data and Safety Monitoring Board for a SARS-CoV-2 vaccine trial and chairs a Data Review Committee for Pulmocide. In the past 3\u00a0years, D.W.D. has been paid for talks on behalf of Hikma, Gilead, BioRad, Basilea, Mylan and Pfizer. D.W.D. is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group, and recently joined the One World Guideline for Aspergillosis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}